BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:22:19 AM | Browse: 417 | Download: 748
 |
Received |
|
2021-06-05 20:31 |
|
Peer-Review Started |
|
2021-06-05 20:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-27 06:26 |
|
Revised |
|
2021-07-28 16:34 |
|
Second Decision |
|
2022-05-24 03:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:44 |
|
Articles in Press |
|
2022-05-28 07:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-22 02:13 |
|
Typeset the Manuscript |
|
2022-07-15 08:11 |
|
Publish the Manuscript Online |
|
2022-07-22 07:22 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tarun Sahu, Henu Kumar Verma and Bhaskar Lvks |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany. henu.verma@yahoo.com |
| Key Words |
COVID-19; Lymphoid malignancy; Lymphoma; Vaccination; Immunosuppression |
| Core Tip |
Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies. |
| Publish Date |
2022-07-22 07:22 |
| Citation |
Sahu T, Verma HK, Lvks B. Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy. World J Virol 2022; 11(4): 204-207 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i4/204.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i4.204 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
